Skip to main content

Tourmaline Bio, Inc.

TRMLDelisted Oct 28, 2025
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827506

Tourmaline Bio, Inc. was delisted on Oct 28, 2025; its insiders filed their last Form 4 on Oct 28, 2025; 134 institutions reported holding it in 13F filings for Q3 2025, worth $1.03B in total; no superinvestor held it.

Key figures

Market cap
–
Not available
Insider buys
0
Open market, last 90 days
Insider sells
0
Open market, last 90 days
13F holders
134
Q3 2025, +25 vs. previous quarter
13F value
$1.03B
Reported value at the end of Q3 2025
Superinvestors holding
0
At the end of Q3 2025

From SEC filings, in USD.

Revenue, FY2024
–
No comparable prior period
Net income, FY2024
-$73.2M
No comparable prior period
Free cash flow, FY2024
-$77.3M
No comparable prior period
Revenue, Q2 FY2025
–
No comparable prior period

Superinvestors holding TRML, Q3 2025

Go to the superinvestors tab

No superinvestor reported holding TRML at the end of Q3 2025.

Latest insider trades

See all insider trades

Open-market purchases and sales by Tourmaline Bio, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 22, 2024 (view filing)Aug 211 dayKulkarni Sandeep ChidambarCEOPPurchase+1.78K$14.85+$26.4K+34.1%7.00K after
Aug 20, 2024 (view filing)Aug 164 daysKulkarni Sandeep ChidambarCEOPPurchase+5.22K$13.79+$72.0KNew position5.22K after
Jan 31, 2024 (view filing)Jan 292 daysMcDade MarkDirectorPPurchase+100.0K$32.50+$3.25M+28.7%448.4K after
Nov 20, 2023 (view filing)Nov 173 daysKulkarni Sandeep ChidambarCEOPPurchase+4.00K$16.99+$68.0K+0.6%729.7K after
Nov 20, 2023 (view filing)Nov 173 daysThiara ParvinderDirectorPPurchase+1.00K$17.31+$17.3K+1.2%83.8K after
Oct 27, 2023 (view filing)Oct 25-272 daysCastelein CaleyDirectorPPurchase+20.0K$14.03+$280.6K+4.0%516.5K after2 lots
Oct 26, 2023 (view filing)Oct 24-262 daysKulkarni Sandeep ChidambarCEOPPurchase+9.65K$11.49+$110.9K+1.3%725.7K after2 lots
Oct 26, 2023 (view filing)Oct 242 daysKantoff AaronDirectorPPurchase+7.50K$11.86+$89.0K+19.8%45.4K after
Oct 26, 2023 (view filing)Oct 24-252 daysThiara ParvinderDirectorPPurchase+7.00K$11.08+$77.5K+9.2%82.8K after2 lots
Jun 14, 2023 (view filing)Jun 12-142 daysIldstad SuzanneDirectorSSale−44.0K$2.55−$112.3K−1.2%3.77M after3 lots10b5-1

Top 10 13F holders, Q3 2025

See all 134 holders

The largest institutional positions in Tourmaline Bio, Inc. at the end of Q3 2025; share changes are against Q2 2025.

Institutions holding TRML in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Avoro Capital Advisors LLC2,555,555$122.2M1.58%00.0%Unchanged
QVT Financial LP2,154,653$103.1M11.44%00.0%Unchanged
BlackRock, Inc.1,517,777$72.6M0.00%−116,165−7.1%Reduced
TCG Crossover Management, LLC1,311,783$62.7M3.09%−165,810−11.2%Reduced
Pfizer Inc1,272,214$60.8M13.91%00.0%Unchanged
Vanguard Group Inc1,165,607$55.8M0.00%−41,428−3.4%Reduced
FIL Ltd1,027,690$49.2M0.04%+1,027,690New
Magnetar Financial LLC966,129$46.2M0.28%+966,129New
Qiming U.S. Ventures Management, LLC741,691$35.5M63.76%00.0%Unchanged
Vivaldi Asset Management, LLC695,757$33.3M2.15%+695,757New

Holders of 5% or more of TRML

See all 3 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Tourmaline Bio, Inc..

Largest holders of TRML from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Avoro Capital Advisors LLC13G/A9.95%2.56M shares–Nov 14, 20242 filingsAug 14, 2025SEC
QVT Financial LP13G/A8.39%2.15M shares+2.65 ppfrom 5.74%May 15, 20252 filingsAug 14, 2025SEC
BlackRock, Inc.13G/A5.50%1.41M shares–Oct 22, 20243 filingsOct 17, 2025SEC